{
    "nctId": "NCT02424682",
    "briefTitle": "Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer",
    "officialTitle": "Safety of Herceptin in Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 69,
    "primaryOutcomeMeasure": "Percentage of Participants with Adverse Events (AEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed diagnosis of metastatic breast cancer (BC) with HER2-neu overexpression\n* Left Ventricular Ejection Fraction (LVEF) by ECHO or Multi Gated Acquisition Scan (MUGA) \\> 50%\n* Good performance status: Eastern Cooperative Oncology Group (ECOG) scale \\< or = 2 and life expectancy \\> or = 12 weeks\n\nExclusion Criteria:\n\n* Advanced pulmonary disease and severe dyspnea\n* Abnormal laboratory within 14 days prior to registration\n* Peripheral neuropathy \\> grade 2\n* Presence of central nervous system (CNS) metastasis\n* Pregnancy or lactating",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}